ostetic.com
 
NEWS

Berkeley Advanced Biomaterials Granted K053213 Clearance Letter by FDA to Market Bi-Ostetic™ in U.S.

01/30/2003 Berkeley, California. The U.S. Food and Drug Administration has granted K053213 Clearance Letter for two products from Berkeley Advanced Biomaterials, Bi-Ostetic™ granules and Bi-Ostetic™ blocks. The company's Ostetic product line of synthetic bone fillers provides high quality, cost effective solutions for orthopedic care. READ MORE >>

Berkeley Advanced Biomaterials Announces
New Chief Operating Officer and Clinical Director.

01/16/2003 Berkeley, California. Berkeley Advanced Biomaterials announced two key hires today. The company has appointed Steven Damron as Chief Operating Officer and Ken Trauner, MD as Clinical Director. READ MORE >>

Berkeley Advanced Biomaterials Granted K053213 Clearance Letter by FDA to Market Cem-Ostetic™ Injectable Putty in U.S.

01/09/2003 Berkeley, California. The U.S. Food and Drug Administration has granted K053213 Clearance Letter for an innovative bone fill product from Berkeley Advanced Biomaterials, Cem-Ostetic™ Putty. READ MORE >>


 
01.30.2003
Berkeley Advanced Biomaterials Granted K053213 Clearance Letter by FDA to Market Bi-OsteticTM >>>
01.16.2003
COO and Clinical Director Join Berkeley Advanced Biomaterials >>>
01.09.2003
FDA issues K053213 Clearance Letter for Berkeley Advanced Biomaterials Cem-OsteticTM >>>
   © Copyright 2010, Berkeley Advanced Biomaterials Inc. All rights reserved.